Logo image of APLS

APELLIS PHARMACEUTICALS INC (APLS) Stock Fundamental Analysis

NASDAQ:APLS - Nasdaq - US03753U1060 - Common Stock - Currency: USD

17.49  -0.05 (-0.29%)

After market: 17.49 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to APLS. APLS was compared to 568 industry peers in the Biotechnology industry. APLS has a bad profitability rating. Also its financial health evaluation is rather negative. APLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year APLS has reported negative net income.
APLS had a negative operating cash flow in the past year.
APLS had negative earnings in each of the past 5 years.
APLS had a negative operating cash flow in each of the past 5 years.
APLS Yearly Net Income VS EBIT VS OCF VS FCFAPLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

APLS's Return On Assets of -22.36% is fine compared to the rest of the industry. APLS outperforms 76.76% of its industry peers.
APLS has a Return On Equity (-86.58%) which is in line with its industry peers.
Industry RankSector Rank
ROA -22.36%
ROE -86.58%
ROIC N/A
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
APLS Yearly ROA, ROE, ROICAPLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

APLS's Gross Margin of 84.93% is amongst the best of the industry. APLS outperforms 87.50% of its industry peers.
APLS's Gross Margin has declined in the last couple of years.
APLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
APLS Yearly Profit, Operating, Gross MarginsAPLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

APLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
APLS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, APLS has more shares outstanding
Compared to 1 year ago, APLS has an improved debt to assets ratio.
APLS Yearly Shares OutstandingAPLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
APLS Yearly Total Debt VS Total AssetsAPLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -1.70, we must say that APLS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of APLS (-1.70) is comparable to the rest of the industry.
A Debt/Equity ratio of 1.98 is on the high side and indicates that APLS has dependencies on debt financing.
The Debt to Equity ratio of APLS (1.98) is worse than 80.99% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.98
Debt/FCF N/A
Altman-Z -1.7
ROIC/WACCN/A
WACC10.2%
APLS Yearly LT Debt VS Equity VS FCFAPLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

2.3 Liquidity

A Current Ratio of 4.25 indicates that APLS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.25, APLS is in line with its industry, outperforming 50.00% of the companies in the same industry.
A Quick Ratio of 3.81 indicates that APLS has no problem at all paying its short term obligations.
The Quick ratio of APLS (3.81) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.25
Quick Ratio 3.81
APLS Yearly Current Assets VS Current LiabilitesAPLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.63% over the past year.
Looking at the last year, APLS shows a very strong growth in Revenue. The Revenue has grown by 97.03%.
Measured over the past years, APLS shows a very strong growth in Revenue. The Revenue has been growing by 127.23% on average per year.
EPS 1Y (TTM)67.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.27%
Revenue 1Y (TTM)97.03%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%45.19%

3.2 Future

APLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.30% yearly.
APLS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.55% yearly.
EPS Next Y28.85%
EPS Next 2Y46.97%
EPS Next 3Y44.55%
EPS Next 5Y34.3%
Revenue Next Year12.58%
Revenue Next 2Y16.68%
Revenue Next 3Y18.14%
Revenue Next 5Y17.55%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
APLS Yearly Revenue VS EstimatesAPLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
APLS Yearly EPS VS EstimatesAPLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

APLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APLS Price Earnings VS Forward Price EarningsAPLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APLS Per share dataAPLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

APLS's earnings are expected to grow with 44.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.97%
EPS Next 3Y44.55%

More info and screens

0

5. Dividend

5.1 Amount

APLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APELLIS PHARMACEUTICALS INC

NASDAQ:APLS (4/25/2025, 4:30:00 PM)

After market: 17.49 0 (0%)

17.49

-0.05 (-0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-28 2025-02-28/bmo
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners103.98%
Inst Owner Change0.38%
Ins Owners4.12%
Ins Owner Change1.14%
Market Cap2.20B
Analysts80.71
Price Target43.91 (151.06%)
Short Float %17.96%
Short Ratio9.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12%
Min EPS beat(2)-50.27%
Max EPS beat(2)26.26%
EPS beat(4)3
Avg EPS beat(4)0.73%
Min EPS beat(4)-50.27%
Max EPS beat(4)26.26%
EPS beat(8)4
Avg EPS beat(8)-1.94%
EPS beat(12)5
Avg EPS beat(12)-3.14%
EPS beat(16)5
Avg EPS beat(16)-10.85%
Revenue beat(2)1
Avg Revenue beat(2)0.68%
Min Revenue beat(2)-3.68%
Max Revenue beat(2)5.05%
Revenue beat(4)3
Avg Revenue beat(4)1.81%
Min Revenue beat(4)-3.68%
Max Revenue beat(4)5.05%
Revenue beat(8)6
Avg Revenue beat(8)14.68%
Revenue beat(12)8
Avg Revenue beat(12)9.62%
Revenue beat(16)10
Avg Revenue beat(16)36.46%
PT rev (1m)-1.59%
PT rev (3m)-4.86%
EPS NQ rev (1m)-4.41%
EPS NQ rev (3m)11.3%
EPS NY rev (1m)-4.01%
EPS NY rev (3m)-7.31%
Revenue NQ rev (1m)-0.88%
Revenue NQ rev (3m)1.26%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)1.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.81
P/FCF N/A
P/OCF N/A
P/B 9.61
P/tB 9.61
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS6.23
BVpS1.82
TBVpS1.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.36%
ROE -86.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.93%
FCFM N/A
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
F-Score4
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 1.98
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.43%
Cap/Sales 0.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.25
Quick Ratio 3.81
Altman-Z -1.7
F-Score4
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)54.61%
Cap/Depr(5y)218.08%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.27%
EPS Next Y28.85%
EPS Next 2Y46.97%
EPS Next 3Y44.55%
EPS Next 5Y34.3%
Revenue 1Y (TTM)97.03%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%45.19%
Revenue Next Year12.58%
Revenue Next 2Y16.68%
Revenue Next 3Y18.14%
Revenue Next 5Y17.55%
EBIT growth 1Y68.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.18%
EBIT Next 3Y58.66%
EBIT Next 5Y43.49%
FCF growth 1Y85.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.23%
OCF growth 3YN/A
OCF growth 5YN/A